A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy (8282-Reduced)
-
- STATUS
- Not Recruiting
-
- End date
- Jan 23, 2028
-
- participants needed
- 200
-
- sponsor
- Novo Nordisk A/S
Updated on 19 May 2025
Online studies
Summary
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
Details
| Condition | Heart Failure |
|---|---|
| Age | 40years - 84years |
| Clinical Study Identifier | NCT06979375 |
| Sponsor | Novo Nordisk A/S |
| Last Modified on | 19 May 2025 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.